Brent A Hanks
Overview
Explore the profile of Brent A Hanks including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
48
Citations
1659
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
31.
Mowery Y, Patel K, Chowdhary M, Rushing C, Roy Choudhury K, Lowe J, et al.
Radiother Oncol
. 2019 Jun;
138:114-120.
PMID: 31252292
Background And Purpose: Antibodies against programmed cell death protein 1 (PD-1) are standard treatments for advanced melanoma. Palliative radiation therapy (RT) is commonly administered for this disease. Safety and optimal...
32.
Gibney G, Hamid O, Lutzky J, Olszanski A, Mitchell T, Gajewski T, et al.
J Immunother Cancer
. 2019 Mar;
7(1):80.
PMID: 30894212
Background: Epacadostat is a potent inhibitor of the immunosuppressive indoleamine 2,3-dioxygenase 1 (IDO1) enzyme. We present phase 1 results from a phase 1/2 clinical study of epacadostat in combination with...
33.
Nghiem P, Bhatia S, Lipson E, Sharfman W, Kudchadkar R, Brohl A, et al.
J Clin Oncol
. 2019 Feb;
37(9):693-702.
PMID: 30726175
Purpose: Merkel cell carcinoma (MCC) is an aggressive skin cancer often caused by the Merkel cell polyomavirus. Clinical trials of programmed cell death-1 pathway inhibitors for advanced MCC (aMCC) demonstrate...
34.
Kwak M, Farrow N, Salama A, Mosca P, Hanks B, Slingluff C, et al.
J Surg Oncol
. 2018 Nov;
119(2):222-231.
PMID: 30481375
There has been a rapid increase in adjuvant therapies approved for treatment following surgical resection of stages III/IV melanoma. We review current indications for adjuvant therapy, which currently includes a...
35.
Zhao F, Evans K, Xiao C, DeVito N, Theivanthiran B, Holtzhausen A, et al.
Cancer Immunol Res
. 2018 Sep;
6(12):1459-1471.
PMID: 30209062
Although anti-PD-1 therapy has improved clinical outcomes for select patients with advanced cancer, many patients exhibit either primary or adaptive resistance to checkpoint inhibitor immunotherapy. The role of the tumor...
36.
Zhao F, Xiao C, Evans K, Theivanthiran T, DeVito N, Holtzhausen A, et al.
Immunity
. 2018 Jan;
48(1):147-160.e7.
PMID: 29343435
Despite recent advances, many cancers remain refractory to available immunotherapeutic strategies. Emerging evidence indicates that the tolerization of local dendritic cells (DCs) within the tumor microenvironment promotes immune evasion. Here,...
37.
Gnjatic S, Bronte V, Rosa Brunet L, Butler M, Disis M, Galon J, et al.
J Immunother Cancer
. 2017 May;
5:44.
PMID: 28515944
As cancer strikes, individuals vary not only in terms of factors that contribute to its occurrence and development, but as importantly, in their capacity to respond to treatment. While exciting...
38.
Lowe J, Perry D, Salama A, Mathews C, Moss L, Hanks B
J Immunother Cancer
. 2016 Dec;
4:89.
PMID: 28031819
Background: Checkpoint inhibitor immunotherapy is becoming an effective treatment modality for an increasing number of malignancies. As a result, autoinflammatory side-effects are also being observed more commonly in the clinic....
39.
Qin R, Olson A, Singh B, Thomas S, Wolf S, Bhavsar N, et al.
Int J Radiat Oncol Biol Phys
. 2016 Jul;
96(1):72-7.
PMID: 27375168
Purpose: Ipilimumab and radiation therapy (RT) are standard treatments for advanced melanoma; preclinical models suggest the potential for synergy. However, limited clinical information exists regarding safety and optimal timing of...
40.
Hanks B
Discov Med
. 2016 Mar;
21(114):135-42.
PMID: 27011049
Emerging data is suggesting that the process of dendritic cell (DC) tolerization is an important step in tumorigenesis. Our understanding of the networks within the tumor microenvironment that functionally tolerize...